CLINICAL_TRIALS
trial_result
· 2017-06-02
Clinical Trial Update: Dose Ranging of GSK2336805 in Combination Therapy [Phase 2]
Summary
Phase 2 dose-ranging study of GSK2336805 in combination therapy for chronic hepatitis C was completed, with results posted in June 2017.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: GlaxoSmithKline | Conditions: Hepatitis C, Chronic | Phase 2 | Status: COMPLETED | Results posted: 2017-06-02